Psychopharmacology

There has been significant improvement in the outcome of many malignancies, which have required balancing anti-tumor immunity and immune toxicity.

Psychiatry has finally crossed into a new paradigm in the treatment of TRD, bringing the glutamate system on board to join the modulation of the monoamine systems.

Traumatic brain injury (TBI) is a public health epidemic. Psychiatric symptoms after TBI are not just common, but also troublesome.

The controversial question of whether to legalize cannabis has emerged front and center as an important issue that deserves a serious and thoughtful dialogue.

Cannabis continues to be the most commonly used illicit drug in the US, and the potential beneficial effects of CBD on cognition in patients with schizophrenia have critical importance.

The profound effects of climate change on mental health have become increasingly difficult to ignore. 

Bupropion is one of the better tolerated antidepressants, but concerns about anxiety, insomnia, and seizures have dampened its popularity. In this podcast, we’ll see how well those concerns hold up to the evidence.

Substance use disorders are a common comorbidity in individuals with bipolar disorder. Adding cariprazine to their medication regimen may improve symptoms of both disorders.

With a combined 70+ years of clinical experience, the authors discuss scenarios that represent two possible outcomes of discontinuing serotonergic antidepressants.

Two compelling case reports provide additional evidence for potential mechanistic associations between the immune system and schizophrenia.

Antipsychotic drugs are the cornerstone in the management of psychotic disorders, but most patients fail to have a “good” response in short-term trials. Alternative strategies are presented here.

Recent studies and meta-analyses discussed here address mental health hospitalization, optimal treatment, and long-term outcome for children and adolescents with anxiety disorders.

Are mood stabilizers causing strokes? Can we treat bipolar II without medication? The past year brought answers to these questions and more.

Study findings suggest that quetiapine is not a major teratogen, but the risk of malformations must be considered in the context of therapeutic risk-benefit balance.

While many deaths due to opioid overdoses are accidental, there a growing body of evidence that some cases were intentional and that the presence of pain played a role in the decision to end life.

Should hallucinogens such as ketamine, MDMA, psilocybin, and LSD be considered as treatment options for patients with mental illness?

Despite the proven efficacy and safety of medications for ADHD, abuse is a growing concern.

Seven common questions about addiction clinicians regularly hear-as well as the answers.

Recent findings suggest that the magnitude of efficacy for most antidepressants compared with placebo may be more modest than previously thought.

A novel compound holds promise for addressing cognitive deficits in schizophrenia.

An exploration of findings from contemporary research that hint at the unexplored hallucinogenic potential of ketamine and considerations for future investigation.

No better time than the summer to digest and reflect on the richness of our field and how we can implement advances in our own work.

A review of systemic medications for dermatologic diseases describes a wide range of adverse events, which range from mild and reversible to permanent and potentially fatal.

The impetus to consider inflammation as potentially relevant to the pathoetiology of domain-based psychopathology (eg, anhedonia) and/or mental disorders, is provided by a confluence of factors discussed here.